Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Area of Science:

• Immunology
• Gastroenterology

Background:

• Etrolizumab is a monoclonal antibody targeting the β7 subunit of α4β7 and αEβ7 integrins.
• Ulcerative colitis (UC) is a chronic inflammatory bowel disease requiring novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of etrolizumab in patients with moderately-to-severely active ulcerative colitis.
• To assess etrolizumab's potential as a unique therapeutic strategy for UC.

Main Methods:

• A phase 2, double-blind, placebo-controlled, randomized study involving 124 patients with active UC.
• Patients received subcutaneous etrolizumab (100 mg or 420 mg LD + 300 mg) or placebo.
• Primary endpoint: clinical remission at week 10, defined by Mayo Clinic Score (MCS).

Main Results:

• No placebo patients achieved clinical remission at week 10.
• Remission rates were 21% for etrolizumab 100 mg (p=0.0040) and 10% for etrolizumab 300 mg + LD (p=0.048).
• Adverse events were reported in 61% (100 mg), 48% (300 mg + LD), and 72% (placebo) of patients.

Conclusions:

• Etrolizumab significantly increased clinical remission rates at week 10 compared to placebo.
• Targeting α4β7 and αEβ7 integrins presents a promising therapeutic avenue for ulcerative colitis.
• Phase 3 studies are planned to further investigate etrolizumab for UC treatment.